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ABSTRACT
Objective: A series of 5-substituted-4-amino-1, 2, 4-triazole-linked hydroxamic acid derivatives have been synthesized and explored in vitro to 
evaluate antibacterial and antifungal activities.
Methods: Different 5-phenyl group substituted-4-amino-1,2,4-triazole-3-thiol reacted with chlorine substituted hydroxamic acid to produce the 
desired compounds and characterized spectroscopically. Minimum inhibitory concentration (MIC), zone of inhibition (ZOI), growth kinetic studies, 
and scanning electron microscopy (SEM) were employed to elicit the antimicrobial efficacy of synthesized compounds against a wide range of 
bacterial and fungal strains.
Results: Compounds 6a, 6b, 6d, and 6k (MIC of 25 μg/ml) have been found to be more potent against Klebsiella pneumoniae, Bacillus cereus, 
Bacillus pumilus, Micrococcus luteus, and Pseudomonas aeruginosa, compounds 6a-6d, 6k, and 6l (MIC of 25–50 μg/ml) have shown potent antibacterial 
efficacy against Klebsiella pneumonia, P. aeruginosa, and Vibrio cholera compare to the standard drug amoxicillin (MIC of 60 μg/ml, 65 μg/ml, and 
25 μg/ml, respectively). Screening for the antifungal activity revealed that the compounds were found to be most active against Candida albicans (6a, 
6b, and 6l), Candida tropicalis (6b and 6d), and Aspergillus niger (6a, 6b, 6d, and 6j) with MIC of 15–25 μg/ml. Bacteriostatic and fungistatic effect of 
titled compounds was revealed from growth kinetics study.
Conclusion: Electron donating group at the 5-position of the 5-substituted-1,2,4-triazole-linked hydroxamic acid derivatives conferred the biological 
effectiveness of the synthesized compounds and also offer a therapeutically effective prototypical structure for further development of new chemical 
entities with superior antimicrobial activity.
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INTRODUCTION
The microbes are getting resistant toward the existing chemotherapeutics 
in alarming rate which is not only a major concern for public health but 
also a challenge for the scientific community globally, and the number 
of cases of multidrug-resistant bacterial infections is increasing 
nowadays [1]. In clinical practice, the infections caused by the Gram-
positive bacteria are very common. However, the infection caused 
by them is sometime severe. Bacillus cereus, Staphylococcus aureus, 
Bordetella bronchiseptica, Micrococcus luteus, Bacillus pumilus, Bacillus 
subtilis, and Enterococcus faecalis are some important Gram-positive 
bacteria causing serious infection in the community, whereas Salmonella 
typhi, Klebsiella pneumoniae, Vibrio cholerae, Pseudomonas aeruginosa, 
Escherichia coli, and Salmonella typhimurium are very common Gram-
negative bacteria. Among them, E. coli is the most common one. The 
mortality is higher for infections caused by Gram-negative bacteria 
than the Gram-positive one. To overcome various microbial infections 
specifically fungal infection, a large number of triazole drugs have 
been successfully developed [2]. Azole compounds showed the effect 
by inhibiting lanosterol 14α-demethylase (CYP51) which catalyzes the 
oxidative removal of the 14α-methyl group of lanosterol to give Δ14,15-
desaturated intermediates in ergosterol biosynthesis [3] resulting 
in accumulation of toxic methyl-sterols in membranes leading to 
fungistatic or fungicidal effect [4]. Some important azoles derivatives 
such as voriconazole, itraconazole, posaconazole, and fluconazole (Fluc) 
are used for the treatment of fast-growing fungal infections, which are 
the leading cause of mortality and morbidity in immunocompromised 
patients [5]. However, Fluc is not effective against aspergillosis due to 
its severe drug resistance [6,7].
These scenarios are highlighting the urgent need for novel, efficacious, 
less toxic, and safe drug candidates in the pipeline. The heterocyclic 
compounds containing nitrogen, sulfur, and oxygen have an enormous 
significance in the field of medicinal chemistry [8]. To address the 
concern, we develop a series of novel 5-substituted-4-amino-1,2,4-
triazole-linked hydroxamic acid derivatives. Assembling the different 
pharmacophores in a single frame always leads to compounds having 
fascinating biological profile [9]. Triazole is one of the pharmacophores 
in the synthesized compounds. Chemical compounds possess triazole 
as a core; always play a significant role in the field of medicinal 
chemistry. Like triazole, imidazole moiety has widely used to synthesize 
compounds to treat diseases causing by different microorganisms. Even 
though imidazole and triazole have a similar mode of action, triazoles 
have several advantages over imidazole, like, oral bioavailability, 
slow metabolic rate and have minimal effect on sterol synthesis in 
humans. For these, use of triazole moiety increases rather than the 
imidazole [10]. Triazole is well known for its antimicrobial property 
and widely used to treat microorganisms associated diseases [11]. 
Besides, the antibacterial [12-15] and antifungal [16-19] activity; 
1,2,4-triazole possess, anti-inflammatory [20], as well as antioxidants 
properties [21]. Various well-known drug commercialized in the 
market possesses 1,2,4-triazole moiety such as Fluc, terconazole, 
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itraconazole, [22,23] triazolam [24], and ribavirin [25]. Different 
S and N-bridged heterocycles can be synthesized by 1,2,4-triazoles as it 
possesses nucleophilic centers. Triazolothiazines, triazolothiadiazoles, 
triazolothiazepines, triazolothiadiazines, and thiazolotriazoles 
can be synthesized from triazoles, having versatile therapeutic 
potentials. Another moiety in our synthetically designed compounds is 
hydroxamic acid. It is another interesting moiety possess antibacterial, 
antifungal [26,27], anti-inflammatory [28,29], antitumor [30], and 
anticancer agents [31]. Hydroxamic acid and its derivatives can exert 
versatile activity by inhibiting several enzymes, such as urease [32], 
matrix metalloproteinases [33,34], ribonucleotid reductase [35], and 
5-lipoxygenase [36]. Hydroxamic acid has the ability to chelate with 
metals. Few ion exchange resins are built on hydroxamic acids [37]. A 
number of hydroxamic acid derivatives are used as chemotherapeutic 
agents such as ibuproxam, hydroxycarbamide, desferrioxamine B, 
oxametacin, adrafinil, and bufexamac [38]. Hence, considering the above 
fact we have designed and synthesized some novel 5-substituted-4-
amino-1,2,4-triazole-linked hydroxamic acid derivatives and evaluate 
their activity against several Gram-positive, Gram-negative bacteria, and 
a number of fungal strains.
METHODS
All the chemicals were procured from Sigma-Aldrich, India, Spectrochem, 
Merck India Pvt. Ltd., and the media were of purchased from HiMedia. 
Dichloromethane and dimethyl sulfoxide (DMSO) were procured from 
Merck, India; all other chemicals used were of analytical grade. In process 
monitoring of reaction was done on activated silica gel coated plates and 
the solvent system used was n-hexane:ethylacetate. The melting points 
of the synthesized compounds were measured by the capillary method 
and are reported uncorrected. The Fourier-transform infrared (FT-IR) 
spectra were measured in Nicolet iS10 FT-IR Spectrometer (Thermo 
Fisher Scientific, USA), 1H nuclear magnetic resonance (NMR) spectra 
were recorded on AV300 Digital FT NMR Spectrometer, Bruker at 300 
MHz using DMSO-d6 as the solvent and tetramethylsilane as an internal 
standard, 13C NMR spectra were obtained at 500 MHz (Bruker, Germany), 
DMSO-d6 as the solvent. Mass spectra (m/z) of the compounds were 
recorded on JEOL-JMS 700 spectrometer using electron ionization 
technique. Scanning electron microscopy (SEM) study of the synthesized 
compounds was analyzed using SEM JEOL, Tokyo, Japan.
SYNTHETIC PROCEDURE
General procedure for the synthesis of first intermediate 
compound (1a-1f)
Substituted-aryl-acid was taken in a 250 ml rbf. 40 ml of ethanol was added 
to it along with 22.5 ml of conc. sulfuric acid. The mixture was refluxed 
for 2 h on a steam bath. After that, the mixture was cooled and poured 
into crushed ice. The mixture was made strongly alkaline by adding 
sodium carbonate. The mixture was extracted with ether (3×50 ml). The 
combined ether fraction was collected and kept overnight with a small 
amount of activated anhydrous sodium sulfate. The ester in the form of 
oil was collected by means of distilling out the ether.
General procedure for the synthesis of Arylhydrazide (2a-2f)
Esterified compounds (1a-1f) (equimolar) were dissolved in 30 ml of 
ethanol, and hydrazine hydrate (equimolar) was added dropwise in the 
mixture with continuous stirring. The resulting mixture was refluxed 
for 6 h. The solvent was removed by distillation, and the residue was 
cooled to room temperature. The precipitate formed was filtered 
and washed subsequently with water, dried, and recrystallized from 
dehydrated ethanol to yield white crystals.
General procedure for the synthesis of potassium 2-substituted-
hydrazine-1-carbodithioate (3a-3f)
Potassium hydroxide (equimolar) was dissolved in 75 ml of absolute 
alcohol, and arylhydrazide (2a-2f) (equimolar) was added to the 
above solution. The mixture was then cooled in an ice-bath. To this 
mixture carbon disulfide was added (equimolar) in small portions with 
continuous stirring. The reaction mixture was continuously agitated for 
15 h. Finally, the mixture was diluted with 100 ml of anhydrous ether. 
The residue was filtered, washed with ether (3×25 ml), dried and used 
as such for the next reaction.
General procedure for synthesis of 4-amino-5-(substituted-
phenyl)-4H-1,2,4-triazole-3-thiol (4a-4f)
A suspension of potassium 2-substituted hydrazine-1-carbodithioate 
(3a-3f) in 20 ml of water and hydrazine hydrate was refluxed for 
6 h with occasional shaking. Next, the hot mixture was cooled to 
room temperature and diluted with 100 ml of water. Concentrated 
hydrochloric acid was added dropwise to make the reaction mixture 
strongly acidic. The precipitate obtained was filtered, washed 
thoroughly with cold water and dried. The dried product was further 
recrystallized from dehydrated ethanol to get white crystals.
General procedure for the synthesis of substituted-chloro-N-
hydroxyacetamide (5a-5b)
0.01 mol of chloroacetylchloride (to synthesize 5a)/3-chloro 
propionylchloride (to synthesize 5b) was dissolved in 30 ml of 
methanol. To the reaction mixture, hydroxylamine stock solution 
(0.04 mol of hydroxylamine hydrochloride) was dissolved in 12 ml of 
hot methanol. The mixture was stirred for 5 min and to it, a solution 
of 0.06 mol potassium hydroxide in 10 ml of methanol was added 
dropwise. The resulting solution was cooled at room temperature and 
filtered to obtain 2 mol of stock solution was added dropwise and the 
mixture was stirred for 2 h. The precipitate thus obtained was washed 
with ether and recrystallized from methanol.
General procedure for the synthesis of title compounds (6a-6l)
To an equimolar mixture of 4-amino-5-(substituted-phenyl)-4H-1,2,4-
triazole-3-thiol and substituted-chloro-N-hydroxypropanamide in 
acetonitrile, triethylamine was added dropwise and refluxed for 4 
h. After cooling down the reaction mixture to the room temperature, 
20 ml water was added and extracted with chloroform thrice; aqueous 
layer was collected and evaporated to produce solid residue, which 
was further washed with acetone twice and recrystallized from 50% 
ethanolic solution to produce white crystals.
Antimicrobial activity
Microbial strains
In vitro antimicrobial activity was evaluated against 15 different 
pathogenic bacteria include both Gram-negative such as S. typhi 62, 
K. pneumoniae ATCC 10031, Vibrio cholerae VC 20, P. aeruginosa 25619, 
Shigella sonnei NK 4010, E. coli ATCC 25923, and S. typhimurium 
NTCC 74, and Gram-positive such as Bacillus polymyxa 4747, B. cereus 
479, Staphylococcus aureus ATCC 29737, E. faecalis 28, Bordetella 
bronchiseptica 4617, Micrococcus luteus 10240, B. pumilus 148884, 
and Bacillus subtilis 6673, respectively, and seven different fungi 
such as Candida albicans MTCC 183, Candida tropicalis MTCC 2795, 
Cryptococcus neoformans, Aspergillus niger MTCC 281, Microsporum 
gypseum, Penicillium chrysogenum, and Cladosporium sp. All these 
microbial strains were collected from Division of Microbiology and 
Biotechnology, Department of Pharmaceutical Technology, Jadavpur 
University, Kolkata, India.
Preparation of inoculums
Nutrient broth was used to grow the bacterial strains at 37°C for 24 h 
whereas Czapek Dox media were used to culture the fungal strains at 
25–30°C for 48–72 h. Afterward, both the bacterial and fungal strains 
were compared to 0.5 McFarland standards [39] and made the dilution 
with sterile normal saline was so that produced an initial suspension of 
2×106 CFU/ml for further use.
Determination of minimum inhibitory concentration (MIC)
To determine the MIC of the synthesized compounds agar dilution 
method was employed as per the National Committee for Clinical 
Laboratory Standards (NCCLS) 2006 protocol [40]. The synthesized 
compounds were initially dissolved in a suitable solvent and then serial 
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dilution was made to obtain the concentrations 10, 25, 50, 75, 100, 150, 
200, 250, 350, and 400 µg/ml. On the separate agar plates with different 
drug concentrations inocula (2×106 CFU/mL) were spotted and 
incubated for 24 h at 37°C (for bacterial strains). Amoxicillin (Amx) was 
used as a reference standard. Whereas, for fungal strains, unlike agar 
plates, agar media having different drug concentrations were placed as 
a slant in separate test tubes, and the fungal inocula (2×106 CFU/mL) 
were streaked and incubated further for 48–72 h at 28°C. Fluc was used 
as a reference standard. MIC was recorded for any lowest concentration 
where complete growth inhibition of microorganisms was observed 
visually.
Determination of zone of inhibition (ZOI)
The well-diffusion method was used to determine the ZOI. For that 
method, NCCLS 2004 guideline was followed. Briefly, agar plates were 
prepared, and 100µl of bacterial/fungal cell suspension (2×106CFU/mL) 
was spread on solid agar plates using a sterile spreader. Sterile borer was 
used to make the wells, and the tested compounds at their respective 
MIC was added to the wells and incubated for 24 h at 37°C (for bacteria) 
and 48–72 h at 28°C (for fungus). Fluc and Amx were used as a reference 
standard to compare antifungal and antibacterial activity, respectively, 
of the tested compounds. The zone diameters were measured, and the 
experiment was performed in triplicates.
Growth kinetic studies
Growth kinetics studies were carried out to those compounds which 
have shown higher ZOI at their respective MIC as well as for those have 
comparable and significant MIC values against the MIC of standard 
drugs for any bacterial and fungal strains used in the experimental 
design. Thus, selected tested compounds at their concentration of 2× 
MIC were exposed to Gram-positive and Gram-bacteria to carry out the 
study. For any given bacterial strain, 1 ml overnight cultured bacterial 
suspension was taken in two separate test tubes containing 4 ml fresh 
nutrient broth media and incubated for 2–3 h at 37°C. After that in 
one tube, tested compound was added and another tube was used as 
control (without treatment). At each predetermined time point, 100µl 
of bacterial suspension was taken from the tubes, diluted in sterile 
water to achieve the bacterial concentration of 2×106 CFU/mL. From 
that diluted suspension, 100µl was taken to spread on a solid agar plate 
and incubated for 24 h at 37°C. Afterward, a number of the colony was 
counted for both test and control [41].
For fungal strains, fungal spores at a concentration of 1×105 CFU/mL 
were inoculated 1 mL of Czapek Dox medium and incubated with or 
without tested compounds for 48 h with shaking (50 rpm) at 28°C. 
100µl from each medium was taken to dilute in sterile water and spread 
onto Czapek Dox agar plate and incubated at 28°C for 48–72 h, numbers 
of the colony-forming unit were counted for test and control [42].
By calculating the viable counts at each time point, a 24 h time-kill curve 
was plotted by plotting log CFU/mL against time for bacterial strains 
and for fungal strains 96 h time-kill curve were plotted. The experiment 
was performed in triplicates and expressed as mean ± SD.
SEM
Each bacterial and fungal strain was inoculated in two sets, one was 
treated as test and another was control. After 2 h tested, compounds were 
inoculated in tube marked as test. After a sufficient incubation period, 
cultures were centrifuged at 3000 rpm for 10 min, and the supernatant 
was discarded to obtain cells pellet. Cells were resuspended in media 
specific for bacteria and fungus and kept for 10 min and again centrifuged 
at 3000 rpm for 10 min. Fixation of cells was done with 4% glutaraldehyde 
in 0.1 M phosphate buffer and kept for 2–3 h and again centrifuged at 
3000 rpm for 10 min and the supernatant was discarded. Cells were 
washed with sterile water and subjected to dehydration by a series of 
alcohol washing with increasing strength of 30%, 50%, 70%, and 100%, 
respectively. A drop was put on clean glass slide and dried. Platinum 
coating was done and the sample was examined under SEM [43].
In silico target binding study
AutoDock Vina [44] using the Lamarckian genetic algorithm for the 
prediction of binding affinity and searching for the optimum binding 
site together with the AutoDock Tools (ADT) was employed to set up 
and perform blind docking calculations of the triazole derivatives 
binding to substrate binding site of respective enzymes. The membrane 
protein of S. typhi (protein data bank [PDB] id: 4KR4); chimeric CYP51 
(PDB id: chimeric 1EA1); and crystal structure of cytochrome P450 
14-alpha-sterol demethylase (Cyp51) from Mycobacterium tuberculosis 
in complex with azole inhibitors [45] were obtained from the PDB 
(www.rcsb.org/pdb) [46] at a resolution of 1.60 Å was constructed 
using AutoDock4 package to study the target binding interaction of 
all the compounds under study. The coordinates of tested compounds 
were taken from their two-dimensional structures sketched from ACD 
ChemSketch Freeware and converted to the PDB format using Open 
Babel [47].
The target (respective proteins) and the ligand (triazoles) files were 
prepared using ADT. The water molecules were deleted, and polar 
hydrogen atoms and Gasteiger charges were added to both the target 
molecule and the ligands. All other bonds were made rotatable. The 
target was saved in pdbqt format, and a configuration file was created. 
Later docking was run. AutoDock generated nine possible binding 
conformations for each ligand, and the root-mean-square cluster 
tolerance was set to 2.0 Å in each run. The binding mode and interactions 
were analyzed for the significant conformers of the compounds under 
study. All calculations were performed in a Dell system (3.4 GHz 
processor, 2GB RAM, 320 GB Hard disk operating system). For each of 
the docking cases, the lowest energy docked conformation, according 
to the AutoDock scoring function, was selected as the binding mode. 
Visualization of the docked pose was done using PyMOL (The PyMOL 
Molecular Graphics System, Version 1.3, Schrodinger, LLC) molecular 
graphics program.
Docking was processed with setting of the grid sizes for 4KR4; 30, 26, 
and 24 and for chimeric 1EA1 40, 34, and 24 along the X-, Y-, and Z-axes 
with 1Å spacing which covered all the active residues. In a similar way, 
the grid center of each target was set for 4KR4; 34.52, 21.86, and 44.96 
and for chimeric 1EA1 12.04, 2.87, and 62.50 Å for the protein.
Statistical analysis
Experimental data were presented as mean standard deviation. 
One-way analysis of variance was used to determine the statistical 
significance. p<0.01 was considered as statistically significant whereas 
p>0.05 was considered to be statistically not significant.
RESULTS AND DISCUSSION
The synthetic route of the proposed scaffold was depicted in 
Scheme 1. A series of novel 2-((4-amino-5-substituted-4H-1,2,4-
triazol-3-yl)thio)-N-hydroxyacetamide and 3-((4-amino-5-substituted-
4H-1,2,4-triazol-3-yl)thio)-N-hydroxypropanamide(6a-6l) compounds 
were synthesized by reacting 4-amino-5-substituted-4H-1,2,4-triazole-
3-thiol with the respective 2-chloro-N-hydroxy acetamides/3-chloro-N-
hydroxypropanamide (Scheme 1). Briefly, the reaction was carried out 
in three parts, i.e., synthesis of 4-amino-5-substituted-4H-1,2,4-triazole-
3-thiol and synthesis of 2-chloro-N-hydroxy acetamides/3-chloro-N-
hydroxypropanamide then both were coupled to synthesis of the final 
compounds. 4-amino-5-substituted-4H-1,2,4-triazole-3-thiol were 
synthesized by Reid-Heindal method [48], i.e., aryl acids were taken as 
a starting material and refluxed for 2 h with ethanol and concentrated 
sulfuric acid to produce the corresponding aryl esters. The aryl esters 
were further refluxed with hydrazine hydrate to yield corresponding 
aryl hydrazides. Then, in the presence of ethanolic potassium hydroxide, 
the aryl hydrazides were condensed with carbon-di-sulfide to produce 
potassium-3-aroyldithiocarbazates. These aroyldithiocarbazates were 
cyclized to produce corresponding aryl substituted 1,2,4-triazole. In 
another part, chloroacetylchloride or chloropropionylchloride reacted 
with hydroxyl amine hydrochloride to yield 2-chloro-N-hydroxy 
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acetamides or 3-chloro-N-hydroxypropanamide, respectively. In the 
final step, 4-amino-5-(substituted phenyl)-4H-1,2,4-triazole-3-thiol and 
2-chloro-N-hydroxy acetamides or 3-chloro-N-hydroxypropanamide 
were condensed in the presence of triethylamine to produce the final 
compound, i.e., 2-((4-amino-5-substituted-4H-1,2,4-triazol-3-yl)thio)-
N-hydroxyacetamide or 3-((4-amino-5-substituted-4H-1,2,4-triazol-3-
yl)thio)-N-hydroxypropanamide, respectively. All the final compounds 




Yield: 1.2 g (70%), mp: 200–202°C, FTIR (KBR) (cm−1): 3420.39 (N-H 
stretching), 3028.37 (aromatic C-H stretching), 2981.27 (aliphatic 
C-H stretching), 1431.09 (aromatic C=C stretching), 1618.65 (C=O 
stretching), 1530.36 (C=N stretching), 1303.91 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 14.0370 (s; NH), 9.1331 (s; OH), 
8.3740–7.5855 (m; Ar-H), 5.7858 (s; NH2), 1.0373 (s; CH2). 13C-NMR 
(DMSO-d6) δ ppm: 152.4713 (CH), 147.5985 (CH), 124.2174 (CH), 
133.6890 (C), 148.3817 (C), 30.6083 (CH2), 167.2465 (C). Mass: [EI+] 
(C9H10N6O2S) 266 Da; calculated for C9H10N6O2S, C, 40.60; H, 3.79; N, 




Yield: 1 g (73%), mp: 197–200°C, FTIR (KBR) (cm−1): 3412.17 (N-H 
stretching), 3026.40 (aromatic C-H stretching), 2930.53 (aliphatic 
C-H stretching), 1431.34 (aromatic C=C stretching), 1618.84 (C=O 
stretching), 1530.61 (C=N stretching), 1304.29 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 14.0378 (s; NH), 9.1305 (s; 
OH), 8.3704–7.5807 (m; Ar-H), 5.7834 (s; NH2), 1.1560–1.0098 (m; 
CH2-CH2). 13C-NMR (DMSO-d6) δ ppm: 152.4718 (CH), 147.5995 (CH), 
124.2179 (CH), 133.6898 (C), 148.3825 (C), 30.6088 (CH2), 25.7294 
(CH2), 167.2482 (C). Mass: [EI+] (C10H12N6O2S) calc. 280.07 Da, Found: 
280 Da; calculated for C10H12N6O2S, C, 42.85; H, 4.32; N, 29.98; O, 11.42; 
S, 11.44 found: C, 42.92; H, 4.36; N, 29.93; O, 11.39; S, 11.4.
2-((4-amino-5-(4-aminophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxyacetamide (6c)
Yield: 720 mg (768%), mp: 212–215°C, FTIR (KBR) (cm−1): 3372.34 
(N-H stretching), 3038.50 (aromatic C-H stretching), 2918.46 
(aliphatic C-H stretching), 1499.91 (aromatic C=C stretching), 
1693.64 (C=O stretching), 1536.51 (C=N stretching), 1334.46 
(N-N=C stretching).1H-NMR (DMSO-d6, 300 MHz) δ ppm: 12.80011 (s; 
NH), 9.32056 (s; OH), 7.62590–6.52428 (m; Ar- H), 5.91882 (s; NH2), 
1.24555 (m; CH2). 13C-NMR (DMSO-d6) δ ppm: 116.8490 (CH), 120.9804 
Scheme 1: Synthetic route for target compounds 6a–6l
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(CH), 128.4892 (CH), 147.9976 (C), 148.7785 (C), 30.6102 (CH2), 
167.2496 (C). Mass: [EI+] (C10H12N6O2S) calc. 280.07 Da, Found: 280 Da; 
calculated for C10H12N6O2S, C, 42.85; H, 4.32; N, 29.98; O, 11.42; S, 11.44 
found: C, 42.53; H, 4.42; N, 29.82; O, 11.26; S, 11.57.
3-((4-amino-5-(4-aminophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxypropanamide (6d)
Yield: 850 mg (71%), mp: 210–214°C, FTIR (KBR) (cm−1): 3341.13 
(N-H stretching), 3054.69 (aromatic C-H stretching), 2899.90 (aliphatic 
C-H stretching), 1442.34 (aromatic C=C stretching), 1678.97 (C=O 
stretching), 1574.30 (C=N stretching), 1271.78 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 12.7077 (s; NH), 9.4001 (s; OH), 
7.7603–7.2099 (m; Ar- H), 5.2626 (s; NH2), 1.2561 (m; CH2-CH2). 
13C-NMR (DMSO-d6) δ ppm: 116.8498 (CH), 128.4889 (CH), 120.9809 
(C), 147.9981 (C), 148.7789 (C), 30.6109 (CH2), 25.3169 (CH2), 
167.2498 (C). Mass: [EI+] (C11H14N6O2S) calc. 294.09 Da, Found: 294 Da; 
calculated for C11H14N6O2S, C, 44.89; H, 4.79; N, 28.55; O, 10.87; S, 10.89 
found: C, 45.05; H, 4.36; N, 28.76; O, 11.09; S, 10.74.
2-((4-amino-5-(2-mercaptophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxyacetamide (6e)
Yield: 1.12g (70%), mp: 105–109°C, FTIR (KBR) (cm−1): 3367.57 (N-H 
stretching), 3082.03 (aromatic C-H stretching), 2980.41 (aliphatic 
C-H stretching), 1458.46 (aromatic C=C stretching), 1696.7 (C=O 
stretching), 1563.15 (C=N stretching), 1287.18 (N-N=C stretching).1H-
NMR (DMSO-d6, 300 MHz) δ ppm: 13.98857 (s; NH), 9.58518 (s; OH), 
8.04105–7.36677 (m; Ar- H), 5.31007 (s; NH2), 1.36065 (s; CH2). 
13C-NMR (DMSO-d6) δ ppm, 125.1776 (CH), 126.1872 (CH), 127.2028 
(CH), 131.2604 (C), 133.5519 (C), 138.5647 (CH), 148.3655 (C), 
30.6009 (CH2), 165.5395 (C). Mass: [EI+] (C10H11N5O2S2) calc. 297.04Da, 
Found: 297 Da; calculated for C10H11N5O2S2, C, 40.39; H, 3.73; N, 23.55; 
O, 10.76; S, 21.57 found: C, 40.45; H, 4.34; N, 29.94; O, 11.21; S, 11.52.
3-((4-amino-5-(2-mercaptophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxypropanamide (6f)
Yield: 1.3 g (74%), mp: 100–103°C, FTIR (KBR) (cm−1): 3385.76 (N-H 
stretching), 3093.54 (aromatic C-H stretching), 2980.07 (aliphatic 
C-H stretching), 1458.33 (aromatic C=C stretching), 1695.47 (C=O 
stretching), 1562.97 (C=N stretching), 1286.84 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 14.00011 (s; NH), 9.51002 (s; 
OH), 8.03405–7.33288 (m; Ar- H), 5.30011 (s; NH2), 1.37415–1.32802 
(m; CH2-CH2). 13C-NMR (DMSO-d6) δ ppm, 125.1786 (CH), 126.1852 
(CH), 127.2035 (CH), 131.2606 (C), 133.5505 (C), 138.5682 (CH), 
148.4652 (C), 30.6089 (CH2), 25.8079 (CH2), 165.5396 (C). Mass: 
[EI+] (C11H13N5O2S2) calc. 311.05Da, Found: 311 Da; calculated for 
C11H13N5O2S2, C, 42.43; H, 4.21; N, 22.49; O, 10.28; S, 20.60 found: C, 
41.99; H, 4.28; N, 30.06; O, 11.39; S, 11.72.
2-((4-amino-5-(4-nitrophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxyacetamide (6g)
Yield: 1.8 g (80%), mp: 138–140°C, FTIR (KBR) (cm−1): 3343.96 (N-H 
stretching), 3048.17 (aromatic C-H stretching), 2917.92 (aliphatic 
C-H stretching), 1443.74 (aromatic C=C stretching), 1667.23 (C=O 
stretching), 1514.60 (C=N stretching), 1269.08 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 13.64368 (s; NH), 9.30012 (s; 
OH), 7.82233–7.25141 (m; Ar- H), 5.60085 (s; NH2), 1.13647 (m; CH2). 
13C-NMR (DMSO-d6) δ ppm, 129.0487 (CH), 129.2014 (CH), 129.2701 
(CH), 127.9722 (C), 142.9518 (C), 129.3370 (CH), 148.1818 (C), 30.4883 
(CH2), 21.0502 (CH2), 167.2505 (C). Mass: [EI+] (C11H13N5O2S) calc. 279.08 
Da, found: 279 Da; calculated for C11H13N5O2S, C, 47.30; H, 4.69; N, 25.07; O, 
11.46; S, 11.48 found: C, 48.10; H, 4.18; N, 29.86; O, 11.14; S, 11.57.
3-((4-amino-5-(p-tolyl)-4H-1,2 ,4-triazol-3-yl)thio)-N-
hydroxypropanamide (6h)
Yield: 1.4 g (73%), mp: 148–150°C, FTIR (KBR) (cm−1): 3342.98 (N-H 
stretching), 3071.72 (aromatic C-H stretching), 2918.91 (aliphatic 
C-H stretching), 1444.07 (aromatic C=C stretching), 1667.44 (C=O 
stretching), 1515.06 (C=N stretching), 1281.37 (N-N=C stretching).1H-
NMR (DMSO-d6, 300 MHz) δ ppm: 13.67881 (s; NH), 9.37850 (s; OH), 
7.82335–7.25908 (m; Ar- H), 5.59985 (s; NH2), 1.16979–1.12207 (m; 
CH2-CH2). 13C-NMR (DMSO-d6) δ ppm: 129.0512 (CH), 129.2045 (CH), 
129.2723 (CH), 127.9750 (C), 142.9543 (C), 129.3390 (CH), 148.1827 
(C), 30.4859 (CH2), 25.8094 (CH2), 21.0517 (CH3), 167.2530 (C). Mass: 
[EI+] (C12H15N5O2S) calc. 293.09 Da, found: 293 Da; calculated for 
C12H15N5O2S, C, 49.13; H, 5.15; N, 23.87; O, 10.91; S, 10.93 found: C, 
48.98; H, 5.10; N, 29.95; O, 10.97; S, 10.99.
Table 1: MIC values of synthesized compounds (6a-6l)
Organisms MIC (μg/ml)
Bacterial strains 6a 6b 6c 6d 6e 6f 6g 6h 6i 6j 6k 6l Amx
Salmonella typhi 25 25 50 50 - - - - - - 50 100 10
Klebsiella pneumoniae 25 50 25 25 75 100 - - - - - - 60
Bacillus polymyxa 100 100 - - 50 50 - - - - 100 100 32
Bacillus cereus 50 50 50 25 - - - - 50 75 75 50 12
Vibrio cholerae 50 75 - - - - 75 100 - - 50 25 25
Staphylococcus aureus 100 150 100 50 - - - - - - - - 16
Enterococcus faecalis - - - - - - - - 200 200 150 100 25
Bordetella bronchiseptica 50 50 - - 50 50 - - 50 100 - - 25
Micrococcus luteus - - - - - - 100 150 - - 25 25 0.5
Pseudomonas aeruginosa 25 25 50 50 - - - - - - 25 25 65
Shigella sonnei 100 100 - - - - - - - - - - 32
Escherichia coli - - 100 100 - - 100 100 - - 100 100 10
Bacillus pumilus 25 25 50 25 - - - - 50 50 50 75 2
Salmonella typhimurium - - 100 200 200 200 - - - - 150 100 25
Bacillus subtilis 25 25 25 50 - - 100 100 - - 100 150 8
Fungal stains 6a 6b 6c 6d 6e 6f 6g 6h 6i 6j 6k 6l Fluc
Candida albicans 15 25 50 25 - - 100 50 50 100 50 20 12.5
Candida tropicalis 50 20 100 20 - - 200 100 - - - - 10
Candida neoformans 50 50 - - - - 100 200 200 50 50 50 15
Aspergillus niger 20 20 50 25 300 200 100 50 50 25 50 100 18
Microsporum gypseum - - 300 200 - - 500 350 500 300 50 50 16
Penicillium chrysogenum - - 300 250 - - 400 400 - - - - 56
Cladosporium 250 300 - - - - 400 200 250 300 - - 32
Amx: Amoxicillin, Fluc: Fluconazole
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2-((4-amino-5-(4-nitrophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxyacetamide (6i)
Yield: 1.0 g (67%), mp: 223–225°C, FTIR (KBR) (cm−1): 3351.84 (N-H 
stretching), 3070.84 (aromatic C-H stretching), 2939.00 (aliphatic 
C-H stretching), 1451.03 (aromatic C=C stretching), 1698.61 (C=O 
stretching), 1572.72 (C=N stretching), 1288.70 (N-N=C stretching).1H-
NMR (DMSO-d6, 300 MHz) δ ppm: 14.0948 (s; NH), 9.48836 (s; OH), 
8.31648–7.97074 (m; Ar- H), 5.49898 (s; NH2), 1.19998 (m; CH2). 
13C-NMR (DMSO-d6) δ ppm: 122.0874 (CH), 128.4884 (CH), 136.8090 
(C), 147.9985 (C), 148.7815 (C), 30.6092 (CH2), 167.2478 (C). Mass: 
[EI+] (C10H10N6O4S) calc. 310.05 Da, Found: 310 Da; calculated for 
C10H10N6O4S, C, 38.71; H, 3.25; N, 27.08; O, 20.63; S, 10.33 found: C, 
39.76; H, 2.95; N, 26.73; O, 20.48; S, 10.13
3-((4-amino-5-(4-nitrophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxypropanamide (6j)
Yield: 1.2 g (71%), mp: 212–215°C, FTIR (KBR) (cm−1): 3365.73 (N-H 
stretching), 3076.11 (aromatic C-H stretching), 2857.26 (aliphatic 
C-H stretching), 1475.39 (aromatic C=C stretching), 1681.59 (C=O 
stretching), 1519.24 (C=N stretching), 1311.25 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 14.1975 (s; NH), 9.15008 (s; OH), 
8.32100–7.98191 (m; Ar- H), 5.48758 (s; NH2), 1.20831–1.16040 (m; 
CH2-CH2). 13C-NMR (DMSO-d6) δ ppm: 122.0878 (CH), 128.4887 (CH), 
136.8098 (C), 147.9989 (C), 148.7818 (C), 30.6095 (CH2), 25.8370 
(CH2), 167.2482 (C). Mass: [EI+] (C11H12N6O4S) calc. 324.06 Da, found: 
324 Da; calculated for C11H12N6O4S, C, 40.74; H, 3.73; N, 25.91; O, 19.73; 
S, 9.89 found: C, 41.14; H, 3.58; N, 26.06; O, 19.95; S, 10.07.
2-((4-amino-5-(3-nitrophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxyacetamide (6k)
Yield: 1g (70%), mp: 220–224°C, FTIR (KBR) (cm−1): 3308.80 (N-H 
stretching), 3082.67 (aromatic C-H stretching), 2926.24 (aliphatic 
C-H stretching), 1481.03 (aromatic C=C stretching), 1700.90 (C=O 
stretching), 1518.48 (C=N stretching), 1296.15 (N-N=C stretching). 
1H-NMR (DMSO-d6, 300 MHz) δ ppm: 14.1101 (s; NH), 9.4886 (s; OH), 
8.9514–7.8044 (m; Ar- H), 5.8517 (s; NH2), 1.2327 (s; CH2). 13C-NMR 
(DMSO-d6) δ ppm: 121.0683 (CH), 131.2639 (CH), 132.0087 (C), 
133.0016 (CH), 148.0011 (C), 148.9088 (C), 31.8313 (CH2), 165.7338 
(C). Mass: [EI+] (C10H10N6O4S) calc. 310.05 Da, found: 310 Da; calculated 
for C10H10N6O4S, C, 38.71; H, 3.25; N, 27.08; O, 20.63; S, 10.33 found: C, 
38.80; H, 3.29; N, 26.98; O, 20.61; S, 10.30.
3-((4-amino-5-(3-nitrophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-
hydroxypropanamide (6l)
Yield: 1.1 g (70%), mp: 210–212°C, FTIR (KBR) (cm−1):. 1H-NMR 
(DMSO-d6, 300 MHz) δ ppm: 14.1199 (s; NH), 9.4883 (s; OH), 8.9488–
7.1773 (m; Ar- H), 5.8455 (s; NH2), 2.2546 (s; CH2), 1.2186 (s; CH2). 
13C-NMR (DMSO-d6) δ ppm: 121.0678 (CH), 131.2635 (CH), 132.0088 
(C), 133.0010 (CH), 148.0003 (C), 148.9085 (C), 31.8309 (CH2), 25.9689 
(CH2), 165.7335 (C). Mass: [EI+] (C11H12N6O4S) calc. 324.06 Da, found: 
324 Da; calculated for C11H12N6O4S, C, 40.74; H, 3.73; N, 25.91; O, 19.73; 
S, 9.89 found: C, 40.64; H, 3.67; N, 25.99; O, 19.79; S, 9.92.
The synthesized compounds (6a-6l) were exposed to 15 different 
bacterial strains including both Gram-negative and Gram-positive 
bacteria and found to be efficacious at a range of MIC values between 25 
and 200 μg/ml. Amx was used as a reference standard to compare the 
antibacterial activity of the synthesized compounds. The comparative 
MIC values of the compounds were tabulated in Table 1. The results 
showed that majority of the synthesized compounds elicited variable 
degrees of inhibition against the tested microorganisms. Compounds 
6a, 6b, 6c, 6d, 6k, and 6l exhibited potent antibacterial activity against 
K. pneumonia, B. cereus, P. aeruginosa, B. pumilus, S. typhi, B. subtilis, 
and V. cholerae at a MIC of 25 µg/ml whereas compound 6e (75 µg/ml) 
has shown moderate activity compared to the standard having the MIC 
of 60 µg/ml. Compound 6f (100 µg/ml) has poor efficacy against the 
same strain where other compounds have shown no activity. Against 
P. aeruginosa, compounds 6a- 6d, 6k, and 6l (MIC of 25–50 µg/ml) 
have found to be more potent than standard compound (65 µg/ml) 
where other compounds have found to be no activity. Against the other 
bacterial strain compounds have shown moderate to less activity 
compared to the standard like, compound 6e, 6f (50 µg/ml) against 
B. polymyxa; compounds 6a, 6k, and 6l (50 µg/ml) against V. cholerae; 
compounds 6a, 6b, 6e, 6f, and 6i (50 µg/ml) against B. bronchiseptica 
were moderately active where other compounds have mild bioactivity 
against the tested bacterial strains, however, compared to the standard 
they have very less to no activity.
In vitro, antifungal activity was evaluated against seven different fungal 
strains and the result showed that the synthesized compounds were 
active against all tested fungi to some extent (Table 1). Among the tested 
compounds, compound 6a showed potent activity against Candida 
albicans at MIC 15 μg/ml which is nearer to standard Fluc (12.5 μg/ml), 
whereas compound 6l (20 μg/ml) was found to be moderately active 
against Candida albicans. Against A. niger compounds 6a and 6b (20 
μg/ml) were potent whereas compounds 6d and 6j (25 μg/ml) were 
moderately active compared to the standard (18 μg/ml). On the other 
hand, compounds 6b and 6d (20 μg/ml) elicited moderate activity 
against Candida tropicalis.
The ZOI of the compounds which showed inhibitory efficacy against 
individual strains of bacteria and fungus, was calculated at their 
respective MIC and tabulated in Table 2 like, against S. typhi compounds 
6a and 6b showed the ZOI of 18.5±0.2 mm (at MIC of 25 μg/ml) and 
16.5±0.5 mm (at MIC of 25 μg/ml), respectively. Against K. pneumoniae 
compounds 6a, 6c, and 6d showed ZOI of 16.0±0.4 mm, 9.3±0.3 mm, and 
13.8±0.1 mm (at MIC of 25 μg/ml), respectively. Compound 6e showed 
ZOI of 15.4±0.1mm (MIC = 50 μg/ml) against B. polymyxa. Compound 
6l have a ZOI of 13.6±0.2 mm (MIC = 25 μg/ml) against V. cholerae. ZOI 
of 14.7±0.2 mm (MIC = 50 μg/ml) for compound 6d against S. aureus. 
11.4±0.4 mm and 9.5±0.2 mm (MIC = 25 μg/ml) for compounds 6k and 
6l against M. luteus. For compounds 6a, 6b, 6k, and 6l, ZOI was almost 
13mm against P. aeruginosa at MIC of 25 μg/ml. ZOI of 13.3±0.3 mm and 
13.3±0.2 mm were higher for compound 6a against B. pumilus and B. 
subtilis, respectively, at MIC of 25 μg/ml.
For fungal strains, it was observed that compound 6a has the ZOI of 
11.9±0.7 mm (MIC = 15 μg/ml) for C. albicans; compound 6b showed 
9.2±0.9 mm (MIC = 20μg/ml) for C. tropicalis, and against A. niger 
compounds 6a and 6b have shown almost similar ZOI of 11.2 ±0.6mm 
and 11.6 ±0.9 mm, respectively, at the MIC of 20μg/ml.
Compounds 6a, 6b, and 6l were most active against the fungal strain 
C. albicans. It was found very interesting that all of the synthesized 
compounds were active against A. niger even compounds 6e and 6f 
which were not effective against the any of the fungal strain (between 
the tested concentration to determine MIC) used for this experimental 
design, were active against A. niger although the MIC values were high 
enough, i.e., 300μg/ml and 200μg/ml, respectively, compared to the 
standard drug Fluc (18 μg/ml). However, compounds 6b and 6a showed 
potent antifungal activity against A. niger with ZOI of 11.6 ±0.9 mm and 
11.2 ±0.6 mm at the MIC of 20 μg/ml.
SEM was carried out to assess morphological changes in bacterial cells 
following the exposure of most active compounds against selective 
bacterial as well as fungal strains; like, for bacterial strains, B. pumilus 
was treated with compound 6a and P. aeruginosa was treated with 
compound 6b whereas for fungal strains, C. tropicalis was treated with 
compound 6b and C. albicans was treated with compound 6a. The SEM 
analysis showed clear morphological changes in bacterial cells when 
treated with tested compounds. Fig. 1k and l depict the SEM image 
of control and treated B. pumilus, respectively. SEM micrographs of 
B. pumilus revealed that when the bacterium was exposed to the tested 
compound, the cells disrupted following alterations in the cell integrity. 
P. aeruginosa when treated with the tested compound (Fig. 1n), 
appeared to swell with loss of its normal morphology as depicted by 
the control (Fig. 1m). Moreover, based on the pathogenic mechanisms 
of B. pumilus and P. aeruginosa, an alternative strategy for the treatment 
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Fig. 1: Time-dependent in vitro growth curve of Bacillus cereus (a), Klebsiella pneumoniae (b), Vibrio cholerae (c), Bacillus pumilus 
(d), Pseudomonas aeruginosa (e), Bacillus polymyxa (f), Bacillus subtilis (g), Salmonella typhi (h), Staphylococcus aureus (i), 
Micrococcus luteus (j) at their 2×MIC values against test compounds and scanning electron micrograph of B. pumilus (k) before  
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of the infections caused by these organisms is of supreme importance 
in the current scenario.
Fig. 2a and b are the SEM images of control and treated Candida tropicalis, 
respectively, whereas, Fig. 2e and f show the SEM images of control and 
treated Candida tropicalis, respectively. In both the cases, structural changes 
in the SEM studies appeared progressively due to cohesion, diffusibility, 
agglomeration, and ultimate structure distortion and disintegration.
Growth kinetic study was done against the bacterial strains such 
as B. cereus, K. pneumoniae, V. cholerae, B. pumilus, P. aeruginosa, 
B. polymyxa, B. subtilis, S. typhi, S. aureus, and M. luteus for the tested 
compounds which showed higher ZOI at their respective MIC (Fig. 1a-
J, respectively). Whereas, for fugal strains, compounds 6a, 6b, and 6l 
were studied for the growth kinetics evaluation against C. albicans and 
compound 6b for C. tropicalis displayed in Fig. 2c and d, respectively. 
Although almost all synthesized compounds have shown antifungal 
activity against A. niger, the growth kinetic study could not be performed 
as the A. niger strains forming very dark brown spores which could not 
be counted visually. From the growth kinetics data of bacteria as well as 
fungus from Figs. 1 and 2, respectively, it could be observed that the all 
best active compounds showed bacteriostatic and fungistatic activity.
It could be observed from the antimicrobial data that synthesized aryl 
substituted 1,2,4- triazole-linked hydroxamic acid derivatives showed 
moderate to high activity against tested bacterial as well as fungal 
strains. The antifungal enzyme, lanosterol-14α-demethylase is one 
of the primary targets of antifungal drug discovery. The molecular 
mechanism of triazole as an antifungal has already been established. All 
the compounds considered for the study possessed 1,2,4-triazole ring 
in it; therefore, all the compounds exhibited affinity toward the enzyme. 
The intensity of binding was high in compounds 6a, 6b, and 6l, which 
may be due to the ring nitrogen and the electronegative nitro group 
present in the aryl group attached to the central triazole, respectively. 
Triazole is well known for its antimicrobial activity. However, electron-
rich aryl substitutions at 5- position of the 1,2,4-triazole could be an 
added benefit along with the linked hydroxamic acid. For many decades, 
the antimicrobial activity of different hydroxamic acid derivatives was 
evaluated. It was reported that hydroxamic acid is potent as well as 
a specific inhibitor of bacterial urease [49]. Hence, the antimicrobial 
activity of the synthesized compounds might be due to the partial effect 
of hindered urea metabolism by the hydroxamic acid part. It was also 
reported that the presence of -CONHOH group is very much necessary 
for the inhibition of microbial urease. In addition, alkyl group present in 
the hydroxamic acid part of the synthesized compounds influenced the 
effectiveness.
The binding mode of the highest active test compound exhibiting 
appreciable antimicrobial activity was investigated by docking studies. 
Crystal structure of Salmonella typhi was obtained from protein 
repository. On the other hand, no experimental structural information 
on the active site of the target enzyme Candida P450DM is available. It is 
observed from an extensive literature search that high homology exists 
Fig. 4: (a) Cluster of conformers within the active site of the target 
enzyme of Candida albicans (pdb id: Chimeric 1ea1), (b) PoseView 
of standard fluconazole within the active site of 4kr4
ba
Fig. 3: (a) Cluster of conformers within the active site of the 
target protein of Salmonella typhi (pdb id: 4kr4), (b) PoseView of 
standard ampicillin within the active site of 4kr4
ba
Fig. 2: Scanning electron micrograph of Candida tropicalis (a) before treatment, (b) after treatment; Candida albicans (e) before 
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between the mycobacterium P450DM and Candida P450DM. Following 
the method of Rossello et al. [50], the chimeric enzyme for the Candida 
albicans (CACYP51) was developed from that of mycobacterium 
P450DM (MT CYP51) extracted from the PDB (entry code 1EA1). 
The residues that were arranged in a range of 7Å from Fluc were 
substituted with those of Candida P450DM. Substitutions were made 
by replacement of the residues Pro77, Phe78, Met79, Arg96, Met99, 
Leu100, Phe255, Ala256, His258, Ile322, Ile323, and Leu324 by Lys77, 
His78, Leu79, Leu96, Lys99, Phe100, Met255, Gly256, Gln258, His322, 
Ser323, and Ile324, which were thought to be necessary for the ligand-
receptor interaction. Compound 6k, 2-((4-amino-5-(3-nitrophenyl)-
4H-1,2,4-triazol-3-yl)thio)-N-hydroxyacetamide was within the active 
site of 4kr4. The active site composition was procured from rcsb and 
the binding pattern of ampicillin in Fig. 3b was set as standard. Almost 
all the docked conformers occupied the proximal vicinity of the active 
site which is clearly understood from Fig. 3a.
Based on the fact that azoles exhibit antifungal activity by inhibition 
of a cytochrome P450 enzyme, lanosterol-14-α-demethylase during 
the biosynthesis of ergosterol leading to accumulation of 14-α-sterols 
in the fungal cell membrane causing destabilization and membrane 
degradation, it was thought worthwhile to investigate the binding mode 
of the highest active test compound, 6c, 2-((4-amino-5-(4-aminophenyl)-
4H-1,2,4-triazol-3-yl)thio)-N-hydroxyacetamide in the active site of 
chimeric enzyme of cytochrome P450-14-α-sterol demethylase from 
Candida albicans (Candida P450DM) (chimeric 1EA1).
Binding mode analysis of test compound 6c in the active site of chimeric 
1EA1 (Fig. 4a) showed that the test compound was very close to the 
porphyrin ring, HEM 470, similar as that of the cocrystallized ligand 
Fluc. Docking poses of the test compound suggest the presence of active 
site residues leu321, tyr76 as in case of Fluc (Fig. 4b).
CONCLUSION
A series of twelve 5-substituted-1,2,4-triazole-linked hydroxamic acid 
derivatives (6a-6l) were synthesized and evaluated for their in vitro 
antimicrobial potency and found to be potent to moderately active 
in inhibiting the pathogenic growth. The significant antimicrobial 
property may be attributed to the putative substructure of triazole 
(which itself can form ionic interaction with the various microbial 
target; the most acceptable is lanosterol-14α-demethylase in Candida 
albicans) and the salient feature of the hydroxamic group. The aryl 
group with its substituent leaves a mixed opinion with respect to the 
biological interaction. The electron donating ability of methyl, mercapto, 
amino group strengthen the binding affinity of the aryl group with the 
active site of the target might be one of the strong supporting evidence 
for their potency, but in the same ground how this nitro group being 
a strong electron group helps in lifting the chemotherapeutic index is 
difficult to establish. Therefore, the series requires to be well extended. 
Thus, it could be concluded that the synthesized 1,2,4-triazole-linked 
hydroxamic acid derivatives with electron donating groups at 5-position 
of the 1,2,4-triazole moiety may provide a therapeutically effective 
chemical framework from which potential antimicrobial agents may be 
developed further. Therefore, further optimizations of this prototypical 
molecular framework with some diversified molecular fragments may 
generate new drug entities having potent antimicrobial activity.
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